|
|
|
| The Clinical Efficacy of Ritodrine Hydrochloride Tablets Combined with Dydrogesterone in the Treatment of Recurrent Miscarriage Patients |
| ZHAO Ziying, LUO Jing, YU Mengchun |
| Department of Obstetrics and Gynecology, Hengshan District People's Hospital, Yulin Shaanxi 719199 |
|
|
|
|
Abstract 【Objective】 To explore the clinical efficacy of combination of ritodrine hydrochloride tablets and dexamethasone in the treatment of recurrent miscarriage patients.【Methods】A total of 88 patients with recurrent miscarriage admitted to Yan'an University Affiliated Hospital from January 2019 to December 2022 were randomly divided into a control group and an observation group, with 44 cases in each group. The control group was treated with ritodrine hydrochloride tablets, while the observation group was treated with dydrogesterone on the basis of the control group. Both groups received fetal protection treatment until the 70th day of pregnancy. We compared the clinical efficacy, incidence of adverse reactions during treatment, heart rate, blood pressure, progesterone (P), estradiol (E2), and soluble leukocyte antigen G (sHLA-G) levels before and after treatment between two groups.【Results】The total effective rate of the observation group was 93.18%, significantly higher than the control group's 72.73% (P<0.05). After treatment, the blood pressure and heart rate of both groups of patients decreased (P<0.05), and the heart rate and blood pressure of the observation group were lower than those of the control group (P<0.05). After treatment, the serum E2, P, and sHLA-G levels in both groups of patients decreased (P<0.05), and the serum E2, P, and sHLA-G levels in the observation group were on average lower than those in the control group (P<0.05). The total incidence of adverse reactions during treatment in the observation group was lower than that in the control group (P<0.05). 【Conclusion】 The combination of ritodrine hydrochloride tablets and dydrogesterone has a significant effect on the treatment of recurrent miscarriage patients, which can reduce E2 and P levels, reduce the incidence of adverse reactions, and is worthy of clinical promotion and application.
|
|
Received: 29 June 2023
|
|
|
|
|
|
[1] 于晓川,朱芳,吴丹丹. GnRH-a用于中、重度子宫内膜异位症腹腔镜手术后对妊娠的影响[J].中国计划生育学杂志,2022,30(1):42-45.
[2] 陈晓霞,权丽丽. 子宫内膜异位症不孕患者异位内膜组织PAQR3、CAMS、HIF-1α表达及与生育指数关系[J].中国计划生育学杂志,2022,30(8):1819-1822.
[3] 李清雪,张贺玲. 米非司酮联合STAT3抑制药AG490对子宫内膜异位症细胞增殖、凋亡和细胞周期的影响[J].中国临床药理学杂志,2022,38(4):313-317.
[4] 肖继伟,王晓燕,万钰磊. 肺部子宫内膜异位症误诊分析[J].临床误诊误治,2020,33(4):13-17.
[5] 丁霞,邓懿阳,银萍,等. 腹腔镜卵巢子宫内膜异位症保守性手术后复发的危险因素分析及风险预警模型建立[J].蚌埠医学院学报,2022,47(9):1276-1279.
[6] 王莱娜,张萍. 卵巢型子宫内膜异位症初次腹腔镜保守性手术后复发的相关因素分析[J].现代医学,2022,50(2):231-236.
[7] SHAAMASH A H, ALY H A, ABDEL-ALEEM M, et al. Clinical and ultrasound evaluation of early threatened miscarriage to predict pregnancy continuation up to 28 weeks:a prospective cohort study[J].J Ultrasound Med,2020,39(9):1777-1785.
[8] 谢幸, 苟文丽. 妇产科学[M].8版.北京:人民卫生出版社, 2013:36-37.
[9] 于亚莉. 动态监测子宫螺旋动脉血流参数、血清CA125、β-hCG、孕酮在预测早期反复性流产妊娠结局中的临床价值[J].中国妇幼保健,2019,34(6):1331-1334.
[10] 米艳荣,李晓倩,张会保,等. 血清P、β-HCG、E2水平联合经阴道B超预测反复性流产安胎结局的意义[J].中国性科学,2020,29(11):74-77. |
|
|
|
2023, Vol. 40 
